ArticleBMC endocrine disorders2026
Assessment of an innovative synthetic matrix for enhanced cell preservation: evaluating its clinical utility and impact on diagnostic precision in thyroid fine-needle aspiration cytology.
Article in BMC endocrine disorders, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundThyroid nodules are common clinical findings that often require fine-needle aspiration cytology (FNAC) for evaluation. This study aimed to assess the clinical value of Cytomatrix, a commercially available synthetic 3D matrix designed to improve preservation of cytological samples, in enhancing the diagnostic accuracy of thyroid fine-needle aspiration cytology in a standard clinical setting.
methodsA prospective study was conducted at Dr. D Medical Center (Timișoara) between January 2023 and January 2025, involving 80 patients with high-risk thyroid nodules classified as EU-TIRADS 4 or higher (European Thyroid Imaging Reporting and Data System). Each patient underwent FNAC with samples collected using both the conventional smear technique and the Cytomatrix method. Both sample types were processed under standard laboratory conditions with minimal technician involvement. Smears were classified according to the 2023 Bethesda System, and Cytomatrix samples were evaluated using a corresponding Bethesda classification. The diagnostic outcomes of both approaches were compared with each other and against the final histopathological results.
resultsCytomatrix exhibited superior diagnostic performance, achieving a sensitivity of 78.2%, specificity of 96.4%, positive predictive value (PPV) of 90%, and overall accuracy of 91.2%. In comparison, the conventional smear method demonstrated a sensitivity of 69.5%, specificity of 94.7%, PPV of 84.2%, and accuracy of 87.5%. The two methods showed a concordance rate of 76.2%. Cytomatrix notably refined Bethesda classifications by both upgrading and downgrading smear-based diagnoses, aligning more closely with histopathology findings.
conclusionCytomatrix represents a promising addition to traditional FNAC in clinical settings characterized by minimal resource use and reduced technician intervention. Its improved diagnostic accuracy and streamlined processing may enhance thyroid nodule evaluation, contributing to better patient management outcomes. CLINICAL TRIAL NUMBER: Not applicable.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.